BMI
MCID: BDY007
MIFTS: 48

Body Mass Index Quantitative Trait Locus 1 (BMI)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 58 13
Body Mass Index 58 17 3
Bmi 58 49 3
Body Mass Index; Bmi 58
Bmiq1 58

Classifications:



External Ids:

OMIM 58 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM : 58 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). (606641)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 10 and body mass index quantitative trait locus 18. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Leuprolide and Morphine have been mentioned in the context of this disorder. Affiliated tissues include breast, heart and liver.

CDC : 3 Adult BMI Calculator

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 636)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 10 12.7
2 body mass index quantitative trait locus 18 12.7
3 body mass index quantitative trait locus 11 12.6
4 body mass index quantitative trait locus 14 12.6
5 body mass index quantitative trait locus 19 12.6
6 body mass index quantitative trait locus 9 12.5
7 body mass index quantitative trait locus 4 12.5
8 body mass index quantitative trait locus 12 12.5
9 body mass index quantitative trait locus 2 12.5
10 body mass index quantitative trait locus 3 12.5
11 body mass index quantitative trait locus 5 12.5
12 body mass index quantitative trait locus 6 12.5
13 body mass index quantitative trait locus 13 12.5
14 body mass index quantitative trait locus 15 12.5
15 body mass index quantitative trait locus 8 12.4
16 body mass index quantitative trait locus 7 12.4
17 esophageal cancer 11.4
18 chromosome 16p11.2 deletion syndrome, 220-kb 11.4
19 perrault syndrome 1 11.1
20 mental retardation, x-linked 12 11.0
21 morbid obesity and spermatogenic failure 11.0
22 diabetes mellitus 10.8
23 liver disease 10.6
24 gestational diabetes 10.6
25 rere-related disorders 10.5
26 anorexia nervosa 10.5
27 fatty liver disease 10.5
28 asthma 10.5
29 nonalcoholic fatty liver disease 10.5
30 rheumatoid arthritis 10.4
31 atrial fibrillation 10.4
32 lung cancer 10.4
33 kidney disease 10.4
34 adenocarcinoma 10.4
35 coronary heart disease 1 10.4
36 chronic kidney failure 10.4
37 precocious puberty 10.4
38 alzheimer disease 10.4
39 hepatitis 10.4
40 lymphoma 10.4
41 psoriasis 10.4
42 arteries, anomalies of 10.3
43 lipid metabolism disorder 10.3
44 anxiety 10.3
45 sleep apnea 10.3
46 myocardial infarction 10.3
47 bipolar disorder 10.3
48 coronary artery anomaly 10.3
49 liver cirrhosis 10.3
50 pre-eclampsia 10.3

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM:

606641

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53714-56-0 657181 3911
2
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
4
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
5
Chlorhexidine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 55-56-1 2713 9552079
6
Coal tar Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 8007-45-2
7
Meperidine Approved Phase 4,Phase 3 57-42-1 4058
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Ketoprofen Approved, Vet_approved Phase 4,Phase 1 22071-15-4 3825
10
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Nitric Oxide Approved Phase 4,Phase 1,Not Applicable 10102-43-9 145068
13
Povidone-iodine Approved Phase 4,Phase 2,Phase 3,Not Applicable 25655-41-8
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
15
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8
16
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
17
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
18
Clopidogrel Approved Phase 4,Phase 2 120202-66-6, 113665-84-2 60606
19
Ticagrelor Approved Phase 4,Phase 2 274693-27-5 9871419
20
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
21
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
22
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
23
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 68-04-2
24
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
25
Calcium Carbonate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 471-34-1
26
Liraglutide Approved Phase 4,Phase 3,Not Applicable 204656-20-2 44147092
27
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53608-75-6
28
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
30
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
32
Ziprasidone Approved Phase 4,Phase 3,Phase 1,Not Applicable 146939-27-7 60854
33
Chromium Approved Phase 4,Phase 3,Not Applicable 7440-47-3 27668
34
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106266-06-2 5073
35
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
36
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
37
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
38
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
39
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 6055-19-2, 50-18-0 2907
40
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-78-2 2244
41
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 2078-54-8 4943
42
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 112809-51-5 3902
43
Cetrorelix Approved, Investigational Phase 4,Not Applicable 120287-85-6 25074887 16129715
44
Telmisartan Approved, Investigational Phase 4,Not Applicable 144701-48-4 65999
45
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 57-83-0 5994
46
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Not Applicable 116094-23-6 16132418
47
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Not Applicable 133107-64-9
48
Glucagon Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 16941-32-5
49
Magnesium oxide Approved Phase 4,Phase 3,Phase 2 1309-48-4 14792
50
Nicotine Approved Phase 4,Phase 3,Phase 2,Not Applicable 54-11-5 942 89594

Interventional clinical trials:

(show top 50) (show all 4335)
# Name Status NCT ID Phase Drugs
1 Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
2 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
3 Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children Unknown status NCT01878994 Phase 4
4 Children's Healthy Living Program Unknown status NCT01881373 Phase 4
5 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
6 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
7 Treatment of Periodontitis in Obese Individuals Unknown status NCT03103204 Phase 4
8 Intraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication Unknown status NCT01558622 Phase 4 dexketoprofen trometamol;tramadol hydrochloride;pethidine hydrochloride;dexketoprofen trometamol + tramadol hydrochloride;dexketoprofen trometamol + pethidine hydrochloride;vitamin c
9 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
10 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
11 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
12 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity Unknown status NCT00327912 Phase 4
13 Body Composition Measurements in Chronic Heart Failure Unknown status NCT02686866 Phase 4
14 L-arginine Treatment in Mild Hypertension Unknown status NCT02894723 Phase 4
15 Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
16 The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity Unknown status NCT01405352 Phase 4
17 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
18 Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD Unknown status NCT02197871 Phase 4
19 The Therapeutic Effect of Catgut Embedding in Obesity Unknown status NCT02276235 Phase 4
20 Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment Unknown status NCT01865448 Phase 4
21 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
22 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
23 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
24 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
25 Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study Unknown status NCT02409238 Phase 4 Metformin
26 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Unknown status NCT02169570 Phase 4
27 Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
28 Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: "Expect With Me" Unknown status NCT02169024 Phase 4
29 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
30 Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study Unknown status NCT01962402 Phase 4 lorcaserin
31 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
32 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
33 Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
34 Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
35 Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height) Completed NCT00303602 Phase 4 Sublingual orally disintegrating olanzapine (SODO);Oral olanzapine
36 Oral Contraceptives and Body Mass Index Completed NCT01170390 Phase 4 All participants (Aviane);Portia;Aviane
37 Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27 Completed NCT01509365 Phase 4 clopidogrel;clopidogrel
38 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. Completed NCT00356148 Phase 4 Ampicillin/Sulbactam
39 Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years Recruiting NCT03338296 Phase 4 lorcaserin hydrochloride XR;Placebo
40 Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI) Completed NCT01481740 Phase 4 Phenylephrine bolus;phenylephrine infusion
41 Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase Terminated NCT01865695 Phase 4 Creon
42 Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes Completed NCT01232491 Phase 4 Insulin detemir
43 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
44 Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial Completed NCT00203450 Phase 4 Zonegran;Placebo
45 The Effect of Some Parturients' Characteristics on Sensory Block Level After Spinal Anesthesia Recruiting NCT03164096 Phase 4 Bupivacaine Hydrochloride
46 EC PK in Women With Normal and Obese BMI Completed NCT02689804 Phase 4 LNG-EC;UPA-EC
47 Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix Recruiting NCT03202381 Phase 4 Degarelix
48 Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir Enrolling by invitation NCT03374358 Phase 4 Raltegravir
49 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed NCT00845507 Phase 4 Exenatide;Placebo
50 Geodon in Weight Loss Study for Bipolar Disorders Completed NCT00472641 Phase 4 Ziprasidone/Geodon

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

42
Breast, Heart, Liver, Ovary, Testes, Kidney, Prostate

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 4703)
# Title Authors Year
1
Prognostic Value of Combined C-Reactive Protein, Body Mass Index, and Left Ventricular Ejection Fraction in Predicting Cardiovascular Events in Patients ≥80 Years of Age With Acute Myocardial Infarction. ( 30538036 )
2019
2
Body-mass index correlates with severity and mortality in acute pancreatitis: A meta-analysis. ( 30783376 )
2019
3
Pre-pregnancy body mass index and the risk of antenatal depression and anxiety. ( 30733069 )
2019
4
Causal association between body mass index and risk of rheumatoid arthritis: a Mendelian randomization study. ( 30710354 )
2019
5
Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. ( 30898691 )
2019
6
Weight and Risk of Incident Atrial Fibrillation-Body Mass Index Variability or Body Mass Gain? ( 30711114 )
2019
7
Body Mass Index Variability and Long-term Risk of New-Onset Atrial Fibrillation in the General Population: A Korean Nationwide Cohort Study. ( 30711120 )
2019
8
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. ( 30624719 )
2019
9
Levels and Changes in Childhood Body Mass Index in Relation to Risk of Atrial Fibrillation and Atrial Flutter in Adulthood. ( 30649157 )
2019
10
Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF). ( 30527775 )
2019
11
Sex and racial/ethnic differences in the association between childhood attention-deficit/hyperactivity disorder symptom subtypes and body mass index in the transition from adolescence to adulthood in the United States. ( 30629806 )
2019
12
Maternal Pre-pregnancy Body Mass Index and Gestational Weight Gain in Relation to Autism Spectrum Disorder and other Developmental Disorders in Offspring. ( 30575327 )
2019
13
The relationship between body mass index, sex, and postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer. ( 30904219 )
2019
14
Transcriptome Profiles of Human Visceral Adipocytes in Obesity and Colorectal Cancer Unravel the Effects of Body Mass Index and Polyunsaturated Fatty Acids on Genes and Biological Processes Related to Tumorigenesis. ( 30838002 )
2019
15
The association between body mass index and postoperative complications, 30-day mortality and long-term survival in Dutch patients with colorectal cancer. ( 30712552 )
2019
16
Clinical Significance of Gender and Body Mass Index in Asian Patients with Colorectal Cancer. ( 30719166 )
2019
17
Body mass index and diabetes are important prognostic signatures for bilateral breast cancer prognosis. ( 30618092 )
2019
18
Association of body mass index with bladder cancer risk in men depends on abdominal obesity. ( 30806768 )
2019
19
Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause. ( 30666489 )
2019
20
The effect of body mass index on the functional prognosis of traumatic brain injury patients. ( 30689301 )
2019
21
Body Mass Index at Diagnosis as a Prognostic Factor for Early-Stage Invasive Breast Cancer after Surgical Resection. ( 30852575 )
2019
22
Prospective Longitudinal Patient-Reported Satisfaction and Health-Related Quality of Life Following DIEP Flap Breast Reconstruction: Relationship with Body Mass Index. ( 30907803 )
2019
23
The Effect of Smoking and Body Mass Index on The Complication Rate of Alloplastic Breast Reconstruction. ( 30712467 )
2019
24
One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty. ( 30699070 )
2019
25
Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. ( 30871884 )
2019
26
Dental caries experience in relation to body mass index and anthropometric measurements of rural children of Nellore district: A cross-sectional study. ( 30804302 )
2019
27
The potential impact of age, gender, body mass index, socioeconomic status and dietary habits on the prevalence of dental caries among Egyptian adults: a cross-sectional study. ( 30906540 )
2019
28
Effect of body mass index on depression in a UK cohort of 363 037 obese patients: A longitudinal analysis of transition. ( 30838776 )
2019
29
Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial. ( 30835308 )
2019
30
Analysis of Influencing Factors of Poststroke Depression: Is Higher Body Mass Index Always a Risk Factor of Poststroke Depression? ( 30741774 )
2019
31
Relationship Between Body Mass Index, Antidiabetic Agents, and Midterm Mortality in Patients With Both Type 2 Diabetes Mellitus and Acute Coronary Syndrome. ( 30905254 )
2019
32
Exposing the Causal Effect of Body Mass Index on the Risk of Type 2 Diabetes Mellitus: A Mendelian Randomization Study. ( 30891058 )
2019
33
Value of fasting plasma glucose to screen gestational diabetes mellitus before the 24th gestational week in women with different pre-pregnancy body mass index. ( 30829706 )
2019
34
A Multicenter Large-Scale Retrospective Analysis of the Correlation between Body Mass Index and All-Cause Mortality in Patients with Type 2 diabetes Mellitus: A Seven-Year Real-World Study. ( 30773948 )
2019
35
Volumes of coronary plaque disease in relation to body mass index, waist circumference, truncal fat mass and epicardial adipose tissue in patients with type 2 diabetes mellitus and controls. ( 30714400 )
2019
36
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the STELLA-LONG TERM study. ( 30719865 )
2019
37
Body mass index growth trajectories from birth through 24 months in Iranian infants of mothers with gestational diabetes mellitus. ( 30641734 )
2019
38
Diagnostic Accuracy of Body Mass Index and Fasting Glucose for The Prediction of Gestational Diabetes Mellitus after Assisted Reproductive Technology. ( 30644242 )
2019
39
The effect of prepregnancy body mass index on the risk of gestational diabetes mellitus: A systematic review and dose-response meta-analysis. ( 30536891 )
2019
40
Body Mass Index, Change in Weight, Body Weight Variability and Outcomes in Type 2 Diabetes Mellitus (from the ACCORD Trial). ( 30553512 )
2019
41
Relationship Between Body Mass Index and Rehabilitation Outcomes in Subacute Stroke with Dysphagia. ( 30768452 )
2019
42
Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer. ( 30651188 )
2019
43
Impact of Body Mass Index of Japanese Gallbladder Cancer Patients on their Postoperative Outcomes. ( 30820054 )
2019
44
Body mass index stratification in hospitalized Italian adults with congenital heart disease in relation to complexity, diagnosis, sex and age. ( 30795994 )
2019
45
Body mass index in adults with congenital heart disease. ( 30681771 )
2019
46
Low Body Mass Index and Myeloablative Conditioning Regimen Prolong the Duration of Parenteral Nutrition During Hematopoietic Stem Cell Transplantation. ( 30673667 )
2019
47
Risk Factors for Low Bone Density in Inflammatory Bowel Disease: Use of Glucocorticoids, Low Body Mass Index, and Smoking. ( 30799399 )
2019
48
Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding. ( 30898340 )
2019
49
Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A Mendelian Randomization Study. ( 30848805 )
2019
50
Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. ( 30714185 )
2019

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....